Coeptis Therapeutics Stock Performance
| COEP Stock | USD 6.75 0.26 3.71% |
Coeptis Therapeutics holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -1.01, which signifies a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Coeptis Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, Coeptis Therapeutics is expected to outperform it slightly. Use Coeptis Therapeutics maximum drawdown, and the relationship between the information ratio and expected short fall , to analyze future returns on Coeptis Therapeutics.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Coeptis Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Even with relatively uncertain technical and fundamental indicators, Coeptis Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.71) | Five Day Return 21.4 | Year To Date Return 14.21 | Ten Year Return (96.59) | All Time Return (96.59) |
Dividend Date 2020-08-06 | Last Split Date 2020-08-06 |
1 | Coeptis Therapeutics Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy | 10/15/2024 |
2 | Armistice Capital, LLCs Strategic Acquisition in Coeptis Therap - GuruFocus.com | 11/14/2024 |
3 | Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries | 12/03/2024 |
4 | Acquisition by Christine Sheehy of 200000 shares of Coeptis Therapeutics at 1.6 subject to Rule 16b-3 | 12/04/2024 |
5 | Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies | 12/26/2024 |
6 | Why Is Coeptis Therapeutics Stock Falling On Friday | 12/27/2024 |
| Begin Period Cash Flow | 3.8 M |
Coeptis |
Coeptis Therapeutics Relative Risk vs. Return Landscape
If you would invest 356.00 in Coeptis Therapeutics on October 9, 2024 and sell it today you would earn a total of 319.00 from holding Coeptis Therapeutics or generate 89.61% return on investment over 90 days. Coeptis Therapeutics is currently generating 1.7367% in daily expected returns and assumes 13.467% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Coeptis, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Coeptis Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Coeptis Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Coeptis Therapeutics, and traders can use it to determine the average amount a Coeptis Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.129
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | COEP | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.47 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.74 actual daily | 34 66% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Coeptis Therapeutics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Coeptis Therapeutics by adding it to a well-diversified portfolio.
Coeptis Therapeutics Fundamentals Growth
Coeptis Stock prices reflect investors' perceptions of the future prospects and financial health of Coeptis Therapeutics, and Coeptis Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Coeptis Stock performance.
| Return On Equity | -14.81 | ||||
| Return On Asset | -1.87 | ||||
| Current Valuation | 15.05 M | ||||
| Shares Outstanding | 39.72 M | ||||
| Price To Book | 2.99 X | ||||
| Price To Sales | 45.68 X | ||||
| Gross Profit | 75 K | ||||
| EBITDA | (20.16 M) | ||||
| Net Income | (21.27 M) | ||||
| Cash And Equivalents | 2.38 M | ||||
| Cash Per Share | 0.06 X | ||||
| Total Debt | 1.22 M | ||||
| Debt To Equity | 1.89 % | ||||
| Current Ratio | 0.56 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (7.24 M) | ||||
| Earnings Per Share | (0.47) X | ||||
| Market Capitalization | 8.06 M | ||||
| Total Asset | 4.57 M | ||||
| Retained Earnings | (87.36 M) | ||||
| Working Capital | 2.26 M | ||||
About Coeptis Therapeutics Performance
Assessing Coeptis Therapeutics' fundamental ratios provides investors with valuable insights into Coeptis Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Coeptis Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (17.65) | (18.54) | |
| Return On Tangible Assets | (12.13) | (11.52) | |
| Return On Capital Employed | (15.62) | (14.84) | |
| Return On Assets | (5.35) | (5.08) | |
| Return On Equity | (5.67) | (5.95) |
Things to note about Coeptis Therapeutics performance evaluation
Checking the ongoing alerts about Coeptis Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Coeptis Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Coeptis Therapeutics is way too risky over 90 days horizon | |
| Coeptis Therapeutics appears to be risky and price may revert if volatility continues | |
| Coeptis Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Coeptis Therapeutics currently holds 1.22 M in liabilities with Debt to Equity (D/E) ratio of 1.89, which is about average as compared to similar companies. Coeptis Therapeutics has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Coeptis Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (21.27 M) with profit before overhead, payroll, taxes, and interest of 75 K. | |
| Coeptis Therapeutics currently holds about 2.38 M in cash with (7.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. | |
| Coeptis Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 19.0% of Coeptis Therapeutics shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Why Is Coeptis Therapeutics Stock Falling On Friday |
- Analyzing Coeptis Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Coeptis Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Coeptis Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Coeptis Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Coeptis Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Coeptis Therapeutics' stock. These opinions can provide insight into Coeptis Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Coeptis Stock Analysis
When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.